Nifty
Sensex
:
:
18114.90
60821.62
-63.20 (-0.35%)
-101.88 (-0.17%)

Pharmaceuticals & Drugs - Veterinary

Rating :
42/99

BSE: 512529 | NSE: SEQUENT

195.20
21-Oct-2021
  • Open
  • High
  • Low
  • Previous Close
  •  206.70
  •  208.75
  •  192.45
  •  205.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1486721
  •  2940.95
  •  336.50
  •  136.85

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 4,856.89
  • 61.01
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 5,024.49
  • 0.26%
  • 6.75

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 53.52%
  • 7.17%
  • 19.57%
  • FII
  • DII
  • Others
  • 14.12%
  • 1.49%
  • 4.13%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.69
  • 14.78
  • 9.42

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.05
  • 39.23
  • 11.16

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 36.12
  • -
  • 25.18

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 30.58
  • 34.30

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.85
  • 3.79
  • 4.53

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 60.02
  • 23.17
  • 19.49

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Net Sales
320.51
295.26
8.55%
361.82
300.58
20.37%
358.21
316.42
13.21%
346.27
284.22
21.83%
Expenses
300.35
249.78
20.25%
318.54
255.85
24.50%
291.91
266.44
9.56%
289.88
247.06
17.33%
EBITDA
20.16
45.48
-55.67%
43.28
44.74
-3.26%
66.31
49.98
32.67%
56.39
37.16
51.75%
EBIDTM
6.29%
15.40%
11.96%
14.88%
18.51%
15.80%
16.29%
13.07%
Other Income
2.67
1.55
72.26%
1.37
1.83
-25.14%
2.81
0.98
186.73%
2.64
5.97
-55.78%
Interest
3.02
7.65
-60.52%
3.18
9.33
-65.92%
6.20
9.60
-35.42%
7.36
7.84
-6.12%
Depreciation
12.57
13.03
-3.53%
12.68
13.09
-3.13%
11.58
13.05
-11.26%
13.30
12.46
6.74%
PBT
7.23
26.35
-72.56%
29.01
24.14
20.17%
51.33
28.31
81.31%
29.32
22.83
28.43%
Tax
4.58
7.00
-34.57%
5.49
5.91
-7.11%
11.64
4.25
173.88%
7.96
-1.64
-
PAT
2.65
19.35
-86.30%
23.52
18.23
29.02%
39.69
24.06
64.96%
21.36
24.47
-12.71%
PATM
0.83%
6.55%
6.50%
6.06%
11.08%
7.60%
6.17%
8.61%
EPS
0.04
0.64
-93.75%
0.83
0.68
22.06%
1.50
0.82
82.93%
0.86
0.86
0.00%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
1,386.81
1,361.62
1,179.24
1,039.31
1,030.59
683.57
624.98
465.36
455.46
326.86
345.81
Net Sales Growth
15.91%
15.47%
13.46%
0.85%
50.77%
9.37%
34.30%
2.17%
39.34%
-5.48%
 
Cost Of Goods Sold
711.14
694.65
605.05
543.01
554.23
356.70
311.71
240.72
243.65
181.72
192.27
Gross Profit
675.67
666.96
574.19
496.30
476.36
326.87
313.27
224.65
211.81
145.14
153.53
GP Margin
48.72%
48.98%
48.69%
47.75%
46.22%
47.82%
50.12%
48.27%
46.50%
44.40%
44.40%
Total Expenditure
1,200.68
1,149.55
1,008.92
914.37
919.10
643.03
568.27
444.87
438.68
342.51
308.74
Power & Fuel Cost
-
28.75
24.73
23.06
14.66
12.77
26.51
23.32
22.06
23.53
20.21
% Of Sales
-
2.11%
2.10%
2.22%
1.42%
1.87%
4.24%
5.01%
4.84%
7.20%
5.84%
Employee Cost
-
187.22
165.06
145.95
132.07
106.22
88.62
62.39
48.12
41.47
29.40
% Of Sales
-
13.75%
14.00%
14.04%
12.81%
15.54%
14.18%
13.41%
10.57%
12.69%
8.50%
Manufacturing Exp.
-
99.30
83.24
77.73
59.07
57.63
72.14
54.31
52.30
41.42
27.88
% Of Sales
-
7.29%
7.06%
7.48%
5.73%
8.43%
11.54%
11.67%
11.48%
12.67%
8.06%
General & Admin Exp.
-
58.40
56.37
58.35
70.92
48.60
36.44
33.79
43.58
23.96
13.69
% Of Sales
-
4.29%
4.78%
5.61%
6.88%
7.11%
5.83%
7.26%
9.57%
7.33%
3.96%
Selling & Distn. Exp.
-
50.00
45.16
36.29
36.87
28.78
17.46
20.27
12.30
10.51
9.23
% Of Sales
-
3.67%
3.83%
3.49%
3.58%
4.21%
2.79%
4.36%
2.70%
3.22%
2.67%
Miscellaneous Exp.
-
31.21
29.32
29.98
51.29
32.34
15.40
10.07
16.66
19.91
9.23
% Of Sales
-
2.29%
2.49%
2.88%
4.98%
4.73%
2.46%
2.16%
3.66%
6.09%
4.64%
EBITDA
186.14
212.07
170.32
124.94
111.49
40.54
56.71
20.49
16.78
-15.65
37.07
EBITDA Margin
13.42%
15.57%
14.44%
12.02%
10.82%
5.93%
9.07%
4.40%
3.68%
-4.79%
10.72%
Other Income
9.49
8.36
10.09
8.67
17.20
11.08
14.30
9.96
3.84
4.96
10.48
Interest
19.76
24.38
35.71
32.80
39.70
28.34
38.56
44.37
39.04
33.45
29.99
Depreciation
50.13
50.60
50.62
41.92
53.30
40.07
46.22
32.94
32.60
28.61
22.98
PBT
116.89
145.45
94.08
58.88
35.70
-16.80
-13.77
-46.85
-51.00
-72.75
-5.41
Tax
29.67
32.18
12.03
2.01
13.46
-0.41
2.62
3.39
0.58
-8.06
-3.95
Tax Rate
25.38%
23.55%
12.79%
3.41%
3.03%
2.44%
-19.03%
-40.50%
-0.53%
11.08%
73.01%
PAT
87.22
95.44
69.91
48.66
421.57
-13.83
-18.47
-10.74
-110.49
-64.69
-1.40
PAT before Minority Interest
80.00
104.45
82.05
56.88
430.83
-16.39
-16.39
-11.76
-110.49
-64.69
-1.46
Minority Interest
-7.22
-9.01
-12.14
-8.22
-9.26
2.56
-2.08
1.02
0.00
0.00
0.06
PAT Margin
6.29%
7.01%
5.93%
4.68%
40.91%
-2.02%
-2.96%
-2.31%
-24.26%
-19.79%
-0.40%
PAT Growth
1.29%
36.52%
43.67%
-88.46%
-
-
-
-
-
-
 
EPS
3.51
3.84
2.81
1.96
16.97
-0.56
-0.74
-0.43
-4.45
-2.60
-0.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
727.65
687.10
706.69
647.58
976.79
945.71
91.27
56.73
95.00
122.53
Share Capital
49.67
49.67
49.37
48.75
48.75
47.65
30.48
26.74
23.44
21.34
Total Reserves
670.21
623.34
638.43
581.25
912.49
874.01
26.85
-0.37
59.68
101.19
Non-Current Liabilities
152.69
216.46
214.75
227.13
246.20
299.72
277.55
159.23
144.35
104.79
Secured Loans
62.52
108.88
126.94
85.14
141.76
197.50
249.97
150.52
137.32
80.19
Unsecured Loans
31.18
41.18
20.90
18.40
23.38
13.82
0.35
0.56
0.72
0.88
Long Term Provisions
26.30
13.16
30.50
28.54
34.76
28.66
25.70
8.03
6.09
15.49
Current Liabilities
514.00
514.86
440.41
430.93
663.55
290.37
406.09
405.28
345.41
329.56
Trade Payables
229.56
220.38
209.35
160.49
203.04
143.94
90.94
114.59
150.91
123.94
Other Current Liabilities
100.64
104.98
87.80
106.52
259.26
83.23
107.43
56.80
35.63
75.38
Short Term Borrowings
102.91
147.12
127.36
152.41
194.70
56.04
204.31
226.60
151.76
123.34
Short Term Provisions
80.90
42.38
15.90
11.51
6.54
7.17
3.42
7.29
7.12
6.89
Total Liabilities
1,443.00
1,463.16
1,402.10
1,342.62
1,903.76
1,538.02
921.84
625.82
589.34
562.37
Net Block
536.61
576.57
498.14
475.97
684.33
586.48
474.43
237.59
227.26
229.76
Gross Block
754.21
762.46
638.06
581.74
789.60
643.70
596.25
369.07
330.69
305.11
Accumulated Depreciation
217.60
185.89
139.91
105.77
105.27
57.22
121.82
131.48
103.43
75.35
Non Current Assets
676.33
738.86
795.99
804.61
1,176.02
1,047.48
612.00
359.87
358.31
351.94
Capital Work in Progress
29.84
13.42
22.61
18.04
32.55
23.52
39.06
43.04
88.71
64.07
Non Current Investment
76.94
131.29
179.65
221.73
363.97
360.58
58.04
0.04
1.64
0.04
Long Term Loans & Adv.
32.15
14.40
32.27
31.01
37.51
30.35
36.01
76.06
39.28
55.77
Other Non Current Assets
0.79
3.18
63.31
57.86
57.66
46.54
4.47
3.15
1.42
2.30
Current Assets
766.68
724.30
606.12
538.01
727.74
490.54
309.84
265.94
231.04
210.42
Current Investments
5.66
40.18
0.47
17.34
64.12
66.98
0.58
0.08
0.18
0.28
Inventories
264.36
219.42
200.10
158.57
160.81
135.08
94.36
101.40
85.62
68.24
Sundry Debtors
346.14
318.76
278.25
258.35
254.62
192.39
115.44
83.54
65.81
70.41
Cash & Bank
56.20
75.83
72.04
42.45
47.40
25.30
38.46
36.21
33.00
35.88
Other Current Assets
94.34
14.79
8.51
5.25
200.79
70.80
61.01
44.71
46.44
35.62
Short Term Loans & Adv.
77.52
55.33
46.75
56.05
54.48
46.69
41.86
37.47
36.48
28.84
Net Current Assets
252.68
209.44
165.71
107.08
64.19
200.17
-96.25
-139.34
-114.37
-119.13
Total Assets
1,443.01
1,463.16
1,402.11
1,342.62
1,903.76
1,538.02
921.84
625.81
589.35
562.36

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
114.75
115.33
116.02
45.24
-7.19
-0.05
-23.55
-44.78
-3.82
21.48
PBT
145.45
94.08
58.88
445.79
-16.80
-13.77
-8.37
-109.91
-72.75
-5.41
Adjustment
83.98
91.41
84.47
-313.85
123.31
83.81
35.92
133.52
65.98
46.98
Changes in Working Capital
-70.89
-58.30
-27.95
-77.87
-104.37
-71.46
-53.98
-67.45
2.48
-17.29
Cash after chg. in Working capital
158.55
127.18
115.40
54.06
2.14
-1.42
-26.44
-43.84
-4.28
24.27
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-43.79
-11.85
0.62
-8.83
-9.33
1.37
2.89
-0.95
0.46
-2.79
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
9.65
-72.27
-67.69
7.17
-116.18
-315.83
-154.69
-79.95
-54.89
-66.78
Net Fixed Assets
-4.18
-29.66
-32.63
221.87
-49.63
97.97
38.51
-26.62
-28.82
-41.67
Net Investments
72.52
30.56
-101.61
210.25
0.26
-713.97
-118.07
-10.37
-15.66
-25.20
Others
-58.69
-73.17
66.55
-424.95
-66.81
300.17
-75.13
-42.96
-10.41
0.09
Cash from Financing Activity
-138.75
-42.75
-20.08
-56.96
147.44
308.69
179.41
145.54
34.70
61.94
Net Cash Inflow / Outflow
-14.35
0.31
28.25
-4.55
24.07
-7.19
1.17
20.80
-24.02
16.63
Opening Cash & Equivalents
68.10
67.79
39.54
44.10
20.03
21.85
22.96
3.45
27.37
9.17
Closing Cash & Equivalent
53.74
68.10
67.79
39.54
44.10
20.03
21.83
22.96
3.45
27.37

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
28.98
27.10
27.86
25.85
39.44
38.69
3.76
1.97
7.09
11.48
ROA
7.19%
5.73%
4.14%
26.54%
-0.95%
-1.33%
-1.52%
-18.19%
-11.23%
-0.29%
ROE
15.00%
12.06%
8.63%
54.15%
-1.74%
-3.35%
-28.10%
-201.83%
-62.91%
-1.19%
ROCE
16.25%
12.59%
9.24%
41.28%
0.87%
2.72%
6.93%
-16.09%
-9.86%
6.98%
Fixed Asset Turnover
1.83
1.72
1.74
1.51
0.96
1.03
1.01
1.36
1.08
1.26
Receivable days
87.43
90.45
92.53
90.49
118.40
87.75
74.80
57.30
72.70
64.08
Inventory Days
63.61
63.56
61.85
56.34
78.37
65.41
73.58
71.75
82.12
68.11
Payable days
71.27
80.72
75.36
77.04
104.11
77.28
87.31
115.68
149.32
123.09
Cash Conversion Cycle
79.77
73.29
79.02
69.78
92.66
75.87
61.07
13.36
5.51
9.10
Total Debt/Equity
0.31
0.51
0.47
0.48
0.43
0.34
8.26
15.86
3.74
2.19
Interest Cover
6.60
3.63
2.80
12.19
0.41
0.64
0.81
-1.82
-1.18
0.82

News Update:


  • SeQuent Scientific gets EUGMP approval for tablets dosage manufacturing line in Turkey
    15th Jul 2021, 09:23 AM

    The company has already embarked upon significant expansion in Turkey to meet the growing requirements of the local market

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.